With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...
Zacks Investment Research on MSN
UTHR stock rises 12.5% on promising data from TETON-1 Tyvaso study
Shares of United Therapeutics UTHR rallied 12.5% on Monday after the company unveiled robust data from the phase III TETON-1 ...
United Therapeutics Corporation Strong Buy: phase 3 Tyvaso wins in IPF boost FVC, support summer sNDA and Priority Review ...
Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of ...
2don MSN
United Therapeutics rises on positive study for cornerstone drug. Why shares could run even higher
United Therapeutics stock entered Monday up 7% on the year, but moved higher on the Tyvaso drug trial results.
United Therapeutics recently reported that its Phase 3 TETON-1 trial of nebulized Tyvaso for idiopathic pulmonary fibrosis ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared ...
IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results